Binding site analysis of full-length alpha1a adrenergic receptor using homology modeling and molecular docking.

The recent availability of crystal structure of bovine rhodopsin offers new opportunities in order to approach the construction of G protein coupled receptors. This study focuses the attention on the modeling of full-length alpha(1a) adrenergic receptor (alpha(1a)-AR) due to its biological role and significant implications in pharmacological treatment of benign prostate hyperplasia. This work could be considered made up by two main steps: (a) the construction of full structure of alpha(1a)-AR, through homology modeling methods; (b) the automated docking of an endogenous agonist, norepinephrine, and of an antagonist, WB-4101, using BioDock program. The obtained results highlight the key residues involved in binding sites of both agonists and antagonists, confirming the mutagenesis data and giving new suggestions for the rational design of selective ligands.

[1]  M. Zuscik,et al.  Novel Aromatic Residues in Transmembrane Domains IV and V Involved in Agonist Binding at α1a-Adrenergic Receptors* , 2000, The Journal of Biological Chemistry.

[2]  S. Harrison,et al.  Structure of the DNA-binding domains from NFAT, Fos and Jun bound specifically to DNA , 1998, Nature.

[3]  D. Perez,et al.  The Unique Nature of the Serine Interactions for -Adrenergic Receptor Agonist Binding and Activation (*) , 1996, The Journal of Biological Chemistry.

[4]  P. Mátyus,et al.  α‐Adrenergic approach in the medical management of benign prostatic hyperplasia , 1997 .

[5]  C. Ghio,et al.  Theoretical conformational analysis for neurotransmitters in the gas phase and in aqueous solution. Norepinephrine. , 2003, Journal of the American Chemical Society.

[6]  K. Palczewski,et al.  G protein-coupled receptor rhodopsin: a prospectus. , 2003, Annual review of physiology.

[7]  The Short Tandem Repeat Loci hTPO, THO1 and FGA , 1998, Human Heredity.

[8]  D. Perez,et al.  Activation of the α1b-Adrenergic Receptor Is Initiated by Disruption of an Interhelical Salt Bridge Constraint* , 1996, The Journal of Biological Chemistry.

[9]  M. Piascik,et al.  α1-Adrenergic Receptors: New Insights and Directions , 2001 .

[10]  J. Baldwin,et al.  An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors. , 1997, Journal of molecular biology.

[11]  T L Blundell,et al.  FUGUE: sequence-structure homology recognition using environment-specific substitution tables and structure-dependent gap penalties. , 2001, Journal of molecular biology.

[12]  C. Melchiorre,et al.  Structure-activity relationships in 1,4-benzodioxan-related compounds. Investigation on the role of the dehydrodioxane ring on alpha 1-adrenoreceptor blocking activity. , 1988, Journal of medicinal chemistry.

[13]  G. Tsujimoto,et al.  Cloning, functional expression and tissue distribution of human cDNA for the alpha 1C-adrenergic receptor. , 1993, Biochemical and biophysical research communications.

[14]  N. Guex,et al.  SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling , 1997, Electrophoresis.

[15]  Robert M. Graham,et al.  Non-α-helical elements modulate polytopic membrane protein architecture , 2001 .

[16]  P. Gonzalez-Cabrera,et al.  Phe-308 and Phe-312 in transmembrane domain 7 are major sites of alpha 1-adrenergic receptor antagonist binding. Imidazoline agonists bind like antagonists. , 2001, The Journal of biological chemistry.

[17]  D. Perez,et al.  Identification of critical extracellular loop residues involved in alpha 1-adrenergic receptor subtype-selective antagonist binding. , 1996, Molecular pharmacology.

[18]  S. Vishveshwara,et al.  Geometry of proline-containing alpha-helices in proteins. , 2009, International journal of peptide and protein research.

[19]  T. Sakmar,et al.  Rhodopsin: insights from recent structural studies. , 2002, Annual review of biophysics and biomolecular structure.

[20]  D. Eisenberg,et al.  Assessment of protein models with three-dimensional profiles , 1992, Nature.

[21]  A. IJzerman,et al.  Involvement of Asn-293 in stereospecific agonist recognition and in activation of the beta 2-adrenergic receptor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Brian F. Yates,et al.  Ligand design for α1 adrenoceptor subtype selective antagonists , 2000 .

[23]  D. Mottram,et al.  Receptor interaction for the α‐antagonist WB4101 (2‐(N[2,6‐dimethyoxyphenoxyethyl])amino‐methyl‐1,4‐benzodioxane) , 1978, The Journal of pharmacy and pharmacology.

[24]  Krzysztof Palczewski,et al.  The crystallographic model of rhodopsin and its use in studies of other G protein-coupled receptors. , 2003, Annual review of biophysics and biomolecular structure.

[25]  Alessandro Pedretti,et al.  Modeling of binding modes and inhibition mechanism of some natural ligands of farnesyl transferase using molecular docking. , 2002, Journal of medicinal chemistry.

[26]  Laxmikant V. Kale,et al.  NAMD2: Greater Scalability for Parallel Molecular Dynamics , 1999 .

[27]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.

[28]  Alessandro Pedretti,et al.  VEGA: a versatile program to convert, handle and visualize molecular structure on Windows-based PCs. , 2002, Journal of molecular graphics & modelling.